Shanghai Henlius Overview

  • Year Founded
  • 2009

Year Founded

  • Status
  • Public

  • Employees
  • 4,082

Employees

  • Stock Symbol
  • 02696

Stock Symbol

  • Investments
  • 1

  • Share Price
  • $5.49
  • (As of Friday Closing)

Shanghai Henlius General Information

Description

Shanghai Henlius Biotech Inc is a biopharmaceutical company in China with the vision to offer affordable and biologics for patients with a focus on oncology and autoimmune diseases. The Group is engaged in biopharmaceutical R&D, biopharmaceutical services, and biopharmaceutical production and sales. It operates in Mainland China, Asia Pacific (excluding Mainland China), North America, South America, Oceania, and Europe. The company products include HLX01 Rituximab, HLX02(trastuzumab), and others.

Contact Information

Website
www.henlius.com
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 11th Floor, Building B8, Huaxin Huixiang City
  • Number 188 Yizhou Road, Xuhui District
  • Shanghai, 200233
  • China
+86 021
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Stock Exchange
HKG
Vertical(s)
Corporate Office
  • 11th Floor, Building B8, Huaxin Huixiang City
  • Number 188 Yizhou Road, Xuhui District
  • Shanghai, 200233
  • China
+86 021

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Shanghai Henlius Stock Performance

As of 20-Nov-2026, Shanghai Henlius’s stock price is $5.49. Its current market cap is $2.99B with 545M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$5.49 $5.64 $5.36 - $11.12 $2.99B 545M 971K $0.23

Shanghai Henlius Financials Summary

As of 30-Jun-2026, Shanghai Henlius has a trailing 12-month revenue of $1.06B.

In Thousands,
USD
TTM 30-Jun-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 4,878,602 4,365,228 2,130,327 1,427,698
Revenue 1,062,589 927,038 797,781 762,544
EBITDA 197,692 184,227 184,220 145,756
Net Income 123,954 115,006 114,344 77,177
Total Assets 1,927,532 1,766,703 1,451,695 1,397,112
Total Debt 581,186 514,103 499,745 577,413
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Shanghai Henlius Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Shanghai Henlius‘s full profile, request access.

Request a free trial

Shanghai Henlius Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Shanghai Henlius Biotech Inc is a biopharmaceutical company in China with the vision to offer affordable and biologics f
Drug Discovery
Shanghai, China
4,082 As of 2026

Shanghai, China
 

Shanghai, China
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Shanghai Henlius Competitors (16)

One of Shanghai Henlius’s 16 competitors is Abbisko Medicine, a Formerly VC-backed company based in Shanghai, China.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Abbisko Medicine Formerly VC-backed Shanghai, China
CARsgen Therapeutics Formerly VC-backed Shanghai, China
EMD Serono Corporation Boston, MA
Teva Pharmaceutical Industries Corporation Tel Aviv, Israel
Innovent Biologics Formerly VC-backed Suzhou, China
You’re viewing 5 of 16 competitors. Get the full list »

Shanghai Henlius Patents

Shanghai Henlius Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026219178-A1 Pharmaceutical composition and use thereof Pending 14-Apr-2025
WO-2026214567-A1 Sialidase-b7h3-antibody conjugates and methods of using the same Pending 08-Apr-2025
WO-2026209027-A1 Anti-her2 antibody pharmaceutical formulation Pending 03-Apr-2025
WO-2026145631-A1 Ligand-drug conjugate, preparation method therefor and use thereof Pending 31-Dec-2024
WO-2026130566-A1 Ligand-drug conjugate, preparation method therefor and use thereof Pending 20-Dec-2024
To view Shanghai Henlius’s complete patent history, request access »

Shanghai Henlius Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Shanghai Henlius Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Shanghai Henlius‘s full profile, request access.

Request a free trial

Shanghai Henlius Investments (1)

Shanghai Henlius’s most recent deal was a Joint Venture with Joint Venture (Shanghai Helius / SVAX). The deal was made on 07-Nov-2024.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Joint Venture (Shanghai Helius / SVAX) 07-Nov-2024 Joint Venture Pharmaceuticals
To view Shanghai Henlius’s complete investments history, request access »

Shanghai Henlius ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

25.45 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,593

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Biotechnology

Subindustry

of 431

Rank

Percentile

To view Shanghai Henlius’s complete esg history, request access »

Shanghai Henlius FAQs

  • When was Shanghai Henlius founded?

    Shanghai Henlius was founded in 2009.

  • Where is Shanghai Henlius headquartered?

    Shanghai Henlius is headquartered in Shanghai, China.

  • What is the size of Shanghai Henlius?

    Shanghai Henlius has 4,082 total employees.

  • What industry is Shanghai Henlius in?

    Shanghai Henlius’s primary industry is Drug Discovery.

  • Is Shanghai Henlius a private or public company?

    Shanghai Henlius is a Public company.

  • What is Shanghai Henlius’s stock symbol?

    The ticker symbol for Shanghai Henlius is 02696.

  • What is the current stock price of Shanghai Henlius?

    As of 20-Nov-2026 the stock price of Shanghai Henlius is $5.49.

  • What is the current market cap of Shanghai Henlius?

    The current market capitalization of Shanghai Henlius is $2.99B.

  • What is Shanghai Henlius’s current revenue?

    The trailing twelve month revenue for Shanghai Henlius is $1.06B.

  • Who are Shanghai Henlius’s competitors?

    Abbisko Medicine, CARsgen Therapeutics, EMD Serono, Teva Pharmaceutical Industries, and Innovent Biologics are some of the 16 competitors of Shanghai Henlius.

  • What is Shanghai Henlius’s annual earnings per share (EPS)?

    Shanghai Henlius’s EPS for 12 months was $0.23.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process